ISG15 and melanoma: Our translational data suggests that extracellular ISG15, presumably acting as a cytokine-like molecule in the TME, mediates regulatory activity restraining optimal therapeutic benefit associated with therapeutic delivery of STING agonist ADU-S100, but only in some cases (i.e., in the B16 but not BPR20 melanoma model).